AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18926131
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation and exercise (800 mg calcium supplementation and 1-hour cycling bout per day at 65%-70% of heart rate reserve)
Trial: 12621132
Drug: Aspirin 325
RxNorm normalized name: aspirin 325 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 325 mg per day
Trial: 10554512
Drug: Home i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home i.v. treatment (HIT)
Trial: 10554512
Drug: In-patient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-patient treatment (SIT)
Trial: 26159147
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment, n=44)
Trial: 11737046
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin (IVIG) therapy
Trial: 8509627
Drug: Recombinant interferon‐alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant interferon‐alpha 2a (6 MU, thrice weekly)
Trial: 8509627
Drug: Recombinant or
RxNorm normalized name: ORE-1001
DrugBank: ORE-1001 (DB12271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant or natural interferon‐alpha (3 MU, thrice weekly)
Trial: 8509627
Drug: 12-month schedule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month schedule of interferon administration
Trial: 29792885
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU intranasal vasopressin
Trial: 27458307
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus ipilimumab (10 mg/kg every 3 weeks for a total of four doses)
Trial: 27458307
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus ipilimumab (10 mg/kg)
Trial: 18287163
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 1500 mg/d
Trial: 18287163
Drug: O-(beta-hydroxyethyl)-rutosides (HR)
RxNorm normalized name: Padimate O
DrugBank: Padimate O (DB11570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: O-(beta-hydroxyethyl)-rutosides (HR) 2 g/d
Trial: 18287163
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no pharmacologic or compression treatment)
Trial: 8836663
Drug: MR889, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR889, 500 mg b.i.d. for 4 weeks
Trial: 8836663
Drug: MR889, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR889, 500 mg b.i.d. for 4 weeks (subset with short disease duration)
Trial: 27472565
Drug: CCDS-administered IL
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCDS-administered IL anesthesia
Trial: 25410083
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy (manipulation) with supervised exercise regime
Trial: 19878101
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 20% albumin
Trial: 19878101
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of Ringer's acetate solution
Trial: 12564609
Drug: Sibenadet (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibenadet (500 microg three times daily) plus placebo (twice daily)
Trial: 12564609
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 microg twice daily) plus placebo (three times daily)
Trial: 12564609
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily) plus a second placebo (three times daily)
Trial: 8628600
Drug: Phenobarbital (PB)
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (PB) therapy, 10 mg/kg IV followed by 100 mg orally daily until delivery.
Trial: 25196976
Drug: Ceftolozane/tazobactam (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane/tazobactam (doses ranging from 500 to 3000 mg)
Trial: 21173169
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption (per 10 g ethanol/d)
Trial: 11124286
Drug: Low-dose 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose 5-fluorouracil (3 subconjunctival injections of 5 mg each over 11 postoperative days)
Trial: 1364168
Drug: All antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All antihistamines
Trial: 3974097
Drug: Oral albuterol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral albuterol, 4 mg
Trial: 3974097
Drug: Oral metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metaproterenol sulfate, 20 mg
Trial: 3974097
Drug: Oral terbutaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral terbutaline sulfate, 5 mg
Trial: 26406192
Drug: Tetrax group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrax group (TG) - 15 minutes exercise session 3 times weekly for 4 weeks
Trial: 26406192
Drug: Electrostimulation group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrostimulation group (EG) - 40 minutes electrostimulation of postural muscles 3 times weekly for 4 weeks
Trial: 26420180
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg of vitamin B‐12
Trial: 26420180
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g fish oil
Trial: 26420180
Drug: 1000 μg
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 μg vitamin B‐12 and 2 g fish oil
Trial: 21906811
Drug: TB-403 (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TB-403 (0.3 to 5.0 mg/kg)
Trial: 18362604
Drug: Lidocaine‐prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine‐prilocaine cream (positive control)
Trial: 12356389
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 mg/day) + L-arginine
Trial: 7867175
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patches applied for 12 hours daily for 30 days
Trial: 7867175
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin therapy
Trial: 1959368
Drug: sucralfate (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate (1 g every 6 hrs)
Trial: 1959368
Drug: ranitidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ranitidine (50 mg every 6 hrs)
Trial: 7124567
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of vitamin B6 and magnesium
Trial: 28356136
Drug: Slow continuous
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow continuous infusion with hypertonic saline
Trial: 27108405
Drug: Denosumab (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (60 mg subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Trial: 27108405
Drug: Placebo (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (subcutaneous injections, 6 doses total, starting on day one and every 6 months until 30 months)
Trial: 24074637
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (250-750 mg/day)
Trial: 9935129
Drug: Intermittent dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent dosing of progestin (5 mg twice per week)
Trial: 9935129
Drug: Continuous dosing
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous dosing of progestin (2.5 mg daily)
Trial: 9935129
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (intermittent and continuous dosing)
Trial: 2149829
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 1:200,000 epinephrine (Group L)
Trial: 2149829
Drug: 60 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 micrograms sufentanil without test dose (Group S‐)
Trial: 6987026
Drug: Fluproquazone (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluproquazone (75 to 200 mg)
Trial: 6987026
Drug: Fluproquazone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluproquazone (100 to 150 mg)
Trial: 31707286
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg of vitamin D supplementation
Trial: 31707286
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg of vitamin D supplementation
Trial: 31707286
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 μg of vitamin D)
Trial: 31707286
Drug: 10 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 μg and 25 μg of vitamin D supplementation
Trial: 8971536
Drug: 5‐fluorouracil 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil 5% (5‐FU) topical application plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Trial: 8971536
Drug: CO2 laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2 laser vaporization plus 5‐FU plus Interferon alpha‐2a (IFA alpha‐2a) (high dose)
Trial: 6365156
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day of danazol
Trial: 28295907
Drug: Omission of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omission of HF medication for 48 hours
Trial: 28295907
Drug: Regular medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medication
Trial: 25764513
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of oral cholera vaccine at 14 day interval
Trial: 25764513
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of oral cholera vaccine at 28 day interval
Trial: 23724913
Drug: Chemotherapy (pemetrexed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (pemetrexed 500 mg/m² or docetaxel 75 mg/m² every 3 weeks)
Trial: 20578380
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (analgesic)
Trial: 14762984
Drug: Complementary medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary medicine intervention (specifics not provided)
Trial: 14762984
Drug: Physician MD
RxNorm normalized name: miconazole nitrate Topical Solution [Nail MD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician MD as complementary medicine practitioner
Trial: 14762984
Drug: Teaching complementary
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching complementary medicine in medical and nursing schools
Trial: 14762984
Drug: Knowledge about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge about adverse reactions to complementary therapies
Trial: 14762984
Drug: Legalizing complementary
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Legalizing complementary medicine
Trial: 11000645
Drug: Paroxetine (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (n = 137), starting at 10 mg/d and titrated to a maximum of 40 mg/d
Trial: 11000645
Drug: Problem-solving treatment-primary
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving treatment-primary care (PST-PC; n = 138)
Trial: 8792922
Drug: Mizolastine 10
RxNorm normalized name: mizolastine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizolastine 10 mg once daily (n = 29)
Trial: 27068252
Drug: Cellphone Assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellphone Assisted Remote Observation of Medication Adherence (CAROMA)
Trial: 27068252
Drug: Active study
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active study medication
Trial: 15942151
Drug: Local estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local estrogen cream
Trial: 20102444
Drug: Local estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local estrogen and testosterone cream
Trial: 20102444
Drug: Nonhormonal lubricant
RxNorm normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonhormonal lubricant KY gel (control)
Trial: 17914966
Drug: Lactoferrin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin monotherapy for 8 weeks followed by lactoferrin, interferon, and ribavirin for 24 weeks
Trial: 17914966
Drug: Lactoferrin, interferon,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactoferrin, interferon, and ribavirin combination therapy
Trial: 8853250
Drug: Chronic gastric
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic gastric distension (500 ml balloon)
Trial: 27149465
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 session per week for 3 weeks
Trial: 27149465
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 1 single session
Trial: 27149465
Drug: Radial Extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial Extracorporeal Shock Wave Therapy (rESWT) - 3 sessions
Trial: 18474343
Drug: Low-dose carvedilol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose carvedilol coupled with nurse management
Trial: 7751427
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of sustained-release verapamil in fed subjects
Trial: 7751427
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of sustained-release verapamil in fed subjects
Trial: 7751427
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of sustained-release verapamil in fed subjects (rapid absorbers)
Trial: 2089973
Drug: Oral Amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Amphotericin B (2 g/day)
Trial: 7443592
Drug: Heparin with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin with Intralipid
Trial: 7443592
Drug: Control (Heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Heparin without Intralipid)
Trial: 30324839
Drug: Oral rehydration
RxNorm normalized name: Oral rehydration salt formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydration salts plus health education
Trial: 23384404
Drug: Vancomycin 125
RxNorm normalized name: vancomycin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 125 mg four times/day
Trial: 23384404
Drug: Vancomycin 250
RxNorm normalized name: vancomycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin 250 mg four times/day
Trial: 23384404
Drug: Metronidazole 250
RxNorm normalized name: metronidazole 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 250 mg three times/day
Trial: 23384404
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg three times/day
Trial: 23384404
Drug: Metronidazole (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (any dose)
Trial: 21097838
Drug: Packed RBC
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packed RBC transfusion (15 ml/kg) at high ('liberal') haematocrit thresholds
Trial: 21097838
Drug: Packed RBC
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Packed RBC transfusion (15 ml/kg) at low ('restrictive') haematocrit thresholds
Trial: 16925686
Drug: Probiotics (combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (combination of four probiotic strains)
Trial: 11328901
Drug: Alternative antihypertensive
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative antihypertensive therapy (Control)
Trial: 8026202
Drug: Closer injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closer injection port to the introducer sheath and more open introducer sheath sidearm
Trial: 8026202
Drug: Cold saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold saline injection port of the pulmonary artery catheter downstream of the introducer sheath and closed introducer sidearm
Trial: 2690999
Drug: Minaprine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minaprine (100 mg t.d.s. and 100 mg b.d.)
Trial: 2690999
Drug: Mianserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin (20 mg t.d.s.)
Trial: 962291
Drug: Continuous oestriol
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oestriol succinate therapy (2 mg/day) for three years
Trial: 962291
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without hormone therapy
Trial: 31473331
Drug: Spanish-language self-help
RxNorm normalized name: Spanish thyme oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spanish-language self-help smoking cessation intervention (10 booklets, 9 pamphlets, and a booklet for family and friends mailed monthly over 18 months)
Trial: 25996892
Drug: Darbepoetin low
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin low dose (2 μg/kg)
Trial: 25996892
Drug: Darbepoetin high
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin high dose (10 μg/kg)
Trial: 21557814
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment (intra-arterial thrombolysis with alteplase, possibly associated with mechanical clot disruption and/or retrieval)
Trial: 21557814
Drug: Systemic intravenous
RxNorm normalized name: Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic intravenous thrombolysis with alteplase
Trial: 17563309
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin and oral agents
Trial: 11440218
Drug: norfloxacin 400
RxNorm normalized name: norfloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: norfloxacin 400 mg b.i.d. for 10 d
Trial: 11440218
Drug: ceftibuten 200
RxNorm normalized name: ceftibuten 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ceftibuten 200 mg b.i.d. for 10 d
Trial: 7800216
Drug: Indomethacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (100 mg day 1 + 100 mg day 2)
Trial: 21122176
Drug: Low-sodium physiologically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium physiologically based solution
Trial: 18528671
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) for atopic dermatitis
Trial: 18528671
Drug: Specific immunotherapy
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific immunotherapy (SIT) for food allergies
Trial: 17162712
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate + combined estradiol/norethisterone acetate therapy (GA/CENT)
Trial: 15018017
Drug: Low-dose isotretinoin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose isotretinoin (0.15-0.40 mg/kg per day)
Trial: 15018017
Drug: High-dose isotretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose isotretinoin (0.5-1.0 mg/kg per day)
Trial: 7942583
Drug: Sodium alginate
RxNorm normalized name: Sodium Alginate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium alginate (7.5 g)
Trial: 2452915
Drug: Two enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two enzyme preparations tested
Trial: 2452915
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy
Trial: 29478819
Drug: Vestronidase alfa
RxNorm normalized name: Vestronidase alfa
DrugBank: Vestronidase alfa (DB12366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Vestronidase alfa treatment for 24 weeks